Expression ofc-myc Oncogens Product andras Family Oncogene Products in Various Human Malignant Lymphomas Defined by Immunohistochemical Techniques

Open Access
Publisher Website
Google Scholar
Abstract
The authors studied the expression of c‐myc and ros family oncogene products in 43 cases of malignant lymphoma (ML) using the immunoperoxidase method. Unfixed frozen sections of lymph nodes from four patients with Hodgkin's disease and 39 with non‐Hodgkin's lymphoma, together with normal lymph nodes, were studied by the avidinbiotin‐peroxidase complex (ABC) technique. Two monoclonal antibodies, MYC‐2 raised against recombinant human c‐myc protein (reacting specifically with the c‐myc products P62 and P67) and RASK‐4 (raised against recombinant P21 and reacting specifically with ras‐family product P21) were used. The c‐myc product was detected in nuclei of ML cells and some normal, mainly germinal center, lymphocytes. When the staining intensity shown by normal germinal‐center lymphocytes was graded as positive (+) or weakly positive (±), a very intensely positive reaction (+++ to ++) was observed in 37 cases (86%) of ML, a positive reaction (+) in four cases (93%), and a weakly positive reaction (±) in two cases (4.7%). The ras family oncogene product reaction was intensely positive (++) in two cases (4.7%), positive (+) in 16 cases (37.2%), weakly positive (±) in 13 cases (30.2%), and negative in 12 cases (27.9%). Western blot analysis confirmed an elevated level of c‐myc products in two cases, which showed intense MYC‐2 staining, and of ras family products in one case, which demonstrated intense RASK‐4 staining. The enhanced expression of these gene products may play an important role in lym‐phomagenesis of such cases.